Encellin today announced new clinical progress from its ongoing Phase 1 study evaluating its implantable cell therapy platform for people with type 1 diabetes. The company made the announcement in connection with the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting , reporting non-fibrotic engraftment across all seven participants enrolled in the trial, along with host vascularization at the implant site and identification of transplanted islets in multiple participants. The findings build upon interim results first reported in January 2026 and reflect a larger patient cohort, with analysis of the full clinical dataset ongoing.
"The field has made important advances in developing insulin-producing cells but delivering those cells safely and durably without lifelong immunosuppression remains one of the central challenges," said Crystal Nyitray, Ph.D., C.E.O. and Founder of Encellin. "These clinical findings represent encouraging progress toward addressing that challenge and provide evidence that our approach may support engraftment and vascularization without the fibrotic response that has historically limited implanted cell therapies."
The Phase 1 trial enrolled seven adults with established type 1 diabetes who met eligibility criteria for standard-of-care islet transplantation. Participants received a subcutaneous implant containing allogeneic human islets, with the primary objective of evaluating the safety and tolerability of the implant. Enrollment has been completed, and analysis of the full clinical dataset is underway. [The study is an early-stage, open-label trialand was not designed to measure efficacy.]
If confirmed in larger studies, these findings could represent an important step toward overcoming one of the longstanding barriers to cell replacement therapies: maintaining viable implanted cells without provoking fibrosis or requiring chronic immunosuppression. Beyond type 1 diabetes, the platform is designed to support future applications involving stem cell-derived cells and other protein- or hormone-producing cell therapies for chronic diseases.
To learn more about ISSCR 2026 visit www.isscr2026.org
